Long-term use of glimepiride may improve survival and reduce hospitalizations in hospitalized patients with concomitant type 2 diabetes and chronic HF, researchers reported. In addition, high-dose ...

Glimepiride (Betaglim (4 mg)) is a sulfonylurea antidiabetic agent, prescribed for type 2 diabetes.It works by causing the pancreas to produce insulin. The information provided on this page is ...

Glimepiride (Glisu -4) is a sulfonylurea antidiabetic agent, prescribed for type 2 diabetes.It works by causing the pancreas to produce insulin. The information provided on this page is intended to ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

The efficacy and tolerability of glimepiride was confirmed in this 8-week non-interventional study of patients with type 2 diabetes mellitus. The reduction in HbA 1c levels over the period of the ...

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a Phase 3 clinical study which showed that reductions ...

The price you pay for glimepiride depends on several factors. These include your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help with ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes experienced no difference in cardiovascular autonomic neuropathy measures or B-type ...

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding ...

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a Phase 3 clinical study which showed that reductions ...